Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Parliamentarians To Get Sight Of First COVID-19 Vaccine Contract

Commission Official Denies Any ‘Vaccine Nationalism’

Executive Summary

The advance purchase agreement signed by CureVac and the European Commission for the supply of a coronavirus vaccine is being made available for scrutiny, but only by MEPs and in the confines of the European Parliament.

You may also be interested in...



Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts

The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.

AstraZeneca Applies For EU Approval Of COVID-19 Vaccine

The European Medicines Agency may issue an opinion on approving AstraZeneca’s COVID-19 vaccine by 29 January if the data are robust and complete and any additional data requests are dealt with promptly.

Coronavirus Notebook: UK OKs Moderna Vaccine & Use Of Tocilizumab/Sarilumab In Hospitalized Patients

The EMA explains how to get six doses from a vial of the Pfizer/BioNTech vaccine, while the UK seems isolated in its decision to give the second dose of the vaccine 12 weeks after the first.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel